A Phase 3 interventional study of 20 mg VEC-162 and 50 mg VEC-162 in Insomnia, sponsored by Vanda Pharmaceuticals. Completed at 19 sites in United States. Open to participants aged 21 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2014-10-15.
Sponsored by Vanda Pharmaceuticals · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 903 studies in Sleep Initiation and Maintenance Disorders with a site in United States — 146 open to participants now, 183 under way, 5 of them phase 3. Sleep Initiation and Maintenance Disorders · United States.
Among the 903 studies in Sleep Initiation and Maintenance Disorders with a site in United States, this one is the 75th largest by enrollment of the 855 interventional ones that give a count, is one of 42 that started in 2006, is one of 68 in phase 3, and was the 41st registered.
2,729 studies on the registry are indexed under Sleep Initiation and Maintenance Disorders; 731 are open to participants now.
Browse Sleep Initiation and Maintenance Disorders studies →146 of the 903 studies in Sleep Initiation and Maintenance Disorders with a site in United States are open now. Recruiting first, the newest first:
Florida State University · Sites in United States
Ages 6–13 · Healthy volunteers
University of Pittsburgh · Sites in United States
Ages 65+ · Women only
Eight Sleep Inc. · Sites in United States
Ages 45+ · Healthy volunteers
Proactive Life Inc · Sites in United States
Ages 55+
Spectrum Clinical Research, LLC · Sites in United States
Ages 45–65 · Women only
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 390 Sleep Initiation and Maintenance Disorders studies recruiting now, 153 (39%) set no upper age limit and 207 (53%) stop at 75 or younger; 59 take children under 18; 109 take healthy volunteers.
This study: 21 Years to 50 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
903 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 40 · Phase 2 103 · Phase 3 77 · Phase 4 78
First in 1997; this study’s year is marked. 42 started in 2006.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 411 is above the median of 68 across 2,356 interventional studies indexed under Sleep Initiation and Maintenance Disorders.
Median enrollment 60 across the 855 interventional studies, 72 across the 48 observational. Of the 660 that completed or were terminated, 243 (37%) have results posted.
This tab as a report to print or save as PDF → With an account.
186 of 903 have an industry lead sponsor. The 10 most frequent:
Vanda Pharmaceuticals is the lead sponsor of 82 studies on the registry; 17 are open to participants now.
Of its 33 completed or terminated interventional studies of FDA-regulated products, 22 (67%) have results posted.
Vanda Pharmaceuticals has 4 studies filed under Sleep Initiation and Maintenance Disorders — fewer than ten, so there is no comparison to draw.
78 of the studies in Sleep Initiation and Maintenance Disorders with a site in United States that are under way reach primary completion within a year, 4 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06568367Phase 3Axsome Therapeutics, Inc.Studying Solriamfetol Modulation of TAAR-1, Dopamine, and Norepinephrine in Shift Work Disorder (SUSTAIN) | 2026-12 |
| NCT06655883Phase 3Merck Sharp & Dohme LLCA Study of Suvorexant (MK-4305) for the Treatment of Insomnia Disorder in Participants With Opioid Use Disorder (MK-4305-098) | 2027-06-24 |
| NCT07336277Phase 3Emory UniversitySleep Quality and the Efficacy of a Multimodal Sleep Pathway in Hospitalized Orthopedic Trauma Patients | 2027-07 |
| NCT06953869Phase 3Vanda PharmaceuticalsEvaluating the Effects of Tasimelteon vs. Placebo in Treating Pediatric Insomnia | 2027-11 |
| NCT04278404Duke UniversityPharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS) | 2026-11 |
Add all 78 to your calendar (.ics) → With an account.
Among the 903 studies in Sleep Initiation and Maintenance Disorders with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine the safety and efficacy of VEC-162 compared to placebo to improve sleep parameters in a model of insomnia.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Take orally 30 minutes prior to bedtime.
Drug: Placebo
20 mg taken orally 30 minutes prior to bedtime.
Drug: 20 mg VEC-162
50 mg taken orally 30 minutes prior to bedtime.
Drug: 50 mg VEC-162
100 mg taken orally 30 minutes prior to bedtime.
Drug: 100 mg VEC-162
20 mg VEC-162
50 mg VEC-162
100 mg VEC-162
Placebo
Average Improvement of Latency to Persistent Sleep (LPS)
The average improvement in Latency to persistent sleep (the number of minutes between Lights Off and the onset of at least 10 minutes of persistent sleep, as measured by polysomnography) is defined as the difference observed in the VEC-162 treated subjects compared with placebo treated subjects.
Time frame: Night 1
Average Improvement of Wake After Sleep Onset (WASO)
The average improvement of wake after sleep onset (time spent awake between onset of sleep and lights on, determined by PSG) is defined as the difference observed in the VEC-162 treated subjects compared with placebo treated subjects.
Time frame: Night 1
Recruitment took place at 20 US sites. The first subject was screened on February 9th 2006, the first subject enrolled on March 10th, 2006, and the last subject completed on August 21st 2006.
| Milestone | Placebo | VEC-162 20 mg | VEC-162 50 mg | VEC-162 100 mg |
|---|---|---|---|---|
| Started | 103 | 100 | 103 | 106 |
| Completed | 103 | 100 | 102 | 106 |
| Not completed | 0 | 0 | 1 | 0 |
| Withdrew: Protocol violation- no drug administered | 0 | 0 | 1 | 0 |
The average improvement in Latency to persistent sleep (the number of minutes between Lights Off and the onset of at least 10 minutes of persistent sleep, as measured by polysomnography) is defined as the difference observed in the VEC-162 treated subjects compared with placebo treated subjects.
| minutes | Placebo | VEC-162 20 mg | VEC-162 50 mg | VEC-162 100 mg |
|---|---|---|---|---|
| Average Improvement of Latency to Persistent Sleep (LPS) | 45.8 ± 4.28 | 24.3 ± 4.35 | 19.6 ± 4.31 | 23.1 ± 4.21 |
The average improvement of wake after sleep onset (time spent awake between onset of sleep and lights on, determined by PSG) is defined as the difference observed in the VEC-162 treated subjects compared with placebo treated subjects.
| minutes | Placebo | VEC-162 20 mg | VEC-162 50 mg | VEC-162 100 mg |
|---|---|---|---|---|
| Average Improvement of Wake After Sleep Onset (WASO) | 139.3 ± 7.33 | 115.1 ± 7.46 | 105.6 ± 7.39 | 121.9 ± 7.22 |
The average improvement in Total sleep time (determined by PSG and defined as the number of non-wake minutes between lights off and lights on) is defined as the difference observed in the VEC-162 treated subjects compared with placebo treated subjects.
| Minutes | Placebo | VEC-162 20 mg | VEC-162 50 mg | VEC-162 100 mg |
|---|---|---|---|---|
| Average Improvement in Total Sleep Time (TST) | 317.6 ± 7.65 | 351.4 ± 7.78 | 365.5 ± 7.71 | 347.2 ± 7.53 |
The average improvement in latency to non-awake (length of time elapsed between lights off and first epoch of sleep determined by PSG) is defined as the difference observed in the VEC-162 treated subjects compared with placebo treated subjects.
| Minutes | Placebo | VEC-162 20 mg | VEC-162 50 mg | VEC-162 100 mg |
|---|---|---|---|---|
| Average Improvement in Latency to Non-awake (LNA) | 22.3 ± 2.88 | 11.2 ± 2.93 | 8.0 ± 2.90 | 10.0 ± 2.84 |
Collected over Day 1 through Day 2.. Non-serious events are listed at a 1% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | — | 0/103 (0%) | 5/103 (4.9%) |
| VEC-162 20 mg | — | 0/100 (0%) | 7/100 (7%) |
| VEC-162 50 mg | — | 0/102 (0%) | 5/102 (4.9%) |
| VEC-162 100 mg | — | 0/106 (0%) | 6/106 (5.7%) |
| Event | Placebo | VEC-162 20 mg | VEC-162 50 mg | VEC-162 100 mg |
|---|---|---|---|---|
| NauseaGastrointestinal disorders | 3/103 | 3/100 | 3/102 | 3/106 |
| HeadacheNervous system disorders | 3/103 | 0/100 | 1/102 | 1/106 |
| Dry MouthGastrointestinal disorders | 0/103 | 2/100 | 1/102 | 0/106 |
| Dry ThroatRespiratory, thoracic and mediastinal disorders | 0/103 | 2/100 | 0/102 | 1/106 |
| Abnormal DreamsPsychiatric disorders | 0/103 | 1/100 | 2/102 | 1/106 |
| DyspepsiaGastrointestinal disorders | 0/103 | 0/100 | 1/102 | 2/106 |
Modified Intent-to-Treat. A total of 411 subjects received treatment.
| Age, Continuous(years) | Placebo | VEC-162 20 mg | VEC-162 50 mg | VEC-162 100 mg | Total |
|---|---|---|---|---|---|
| Mean | 30.9 ± 7.28 | 30.8 ± 8.41 | 31.0 ± 8.51 | 31.2 ± 8.19 | 31.0 ± 8.08 |
| Sex: Female, Male(Participants) | Placebo | VEC-162 20 mg | VEC-162 50 mg | VEC-162 100 mg | Total |
|---|---|---|---|---|---|
| Female | 68 | 62 | 58 | 73 | 261 |
| Male | 35 | 38 | 44 | 33 | 150 |
The record gives a start of Feb 2006, a primary completion of Aug 2006 and a completion of Aug 2006. It does not say whether these dates are actual or estimated.
Results were first posted in Oct 2014, 8 years 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tasimelteon
Sleep Initiation and Maintenance Disorders →